Four Lyons & Simmons Attorneys Named to Lawdragon X – The Next Generation 2026
DALLAS–(BUSINESS WIRE)–Lyons & Simmons is proud to announce that four of the firm’s attorneys have been selected to the prestigious Lawdragon X... Read more.
Revenue and Backlog Growth Drive Vision Aerial–Mobix Labs LOI
BOZEMAN, Mont.–(BUSINESS WIRE)–$MOBX #BacklogGrowth—Vision Aerial today announced that Mobix Labs, Inc. (Nasdaq: MOBX) has signed a binding Letter... Read more.
Destination XL Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Destination XL Group, Inc. – DXLG
NEW ORLEANS–(BUSINESS WIRE)–Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”)... Read more.
Beyond Anti-Aging: AV Laboratories Puts Amino Acids at the Forefront of Science-Led Skin Longevity
As the beauty industry moves from anti-aging promises to longevity-focused skin wellness, new research from the AVL Molecular Research Center at the University of... Read more.
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
NEW YORK & PARIS–(BUSINESS WIRE)–Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and... Read more.
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
NEW YORK & PARIS–(BUSINESS WIRE)–Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and... Read more.
Roots Announces Details of its Fiscal 2026 First Quarter Results Conference Call
Company to issue its Fiscal 2026 first quarter results press release on Friday, June 12, 2026 at 7:00 a.m. ET with a conference call to follow at 8:00 a.m. ET TORONTO–(BUSINESS... Read more.
Ferguson Enterprises Inc. (“Company”): Execution of Rule 10b5-1 Plan
NEWPORT NEWS, Va.–(BUSINESS WIRE)–This is an initial notification of a transaction of a person discharging managerial responsibility (“PDMR”) in... Read more.
DFNS Rebrands as the Core Banking Platform for Digital Assets
PARIS–(BUSINESS WIRE)–DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital... Read more.
Phase III FIND‑CKD Results Show Bayer’s KERENDIA® (finerenone) Improved eGFR Slope and Reduced Risk of a Composite Kidney-Cardiovascular Outcome in Adults with Non‑Diabetic Chronic Kidney Disease
Investigational results from FIND-CKD provide full efficacy and safety data and is the fifth consecutive Phase III clinical trial where KERENDIA met its primary... Read more.